MannKind to Present at the 28th Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 28^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 1:30 PM (PST) at the Westin St. Francis in San Francisco, California.

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA®, MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.